Capital Asset Advisory Services LLC Cellectis S.A. Transaction History

Capital Asset Advisory Services LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 14, 2021	SELL	$11.94 - $16.09 $259,635 - $349,877	-21,745 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$14.36 - $20.93 $142,523 - $207,730	-9,925 Reduced 31.34%	21,745 $336,000
Q1 2021 May 13, 2021	BUY	$18.19 - $33.25 $104,828 - $191,619	5,763 Added 22.24%	31,670 $640,000
Q4 2020 Mar 02, 2021	BUY	$15.87 - $31.64 $73,303 - $146,145	4,619 Added 21.7%	25,907 $701,000
Q3 2020 Nov 18, 2020	SELL	$15.7 - $20.84 $14,789 - $19,631	-942 Reduced 4.24%	21,288 $394,000

Q2 2020 Aug 14, 2020	SELL	$8.21 - $21.02 $5,591 - $14,314	-681 Reduced 2.97%	22,230 $383,000
Q1 2020 May 18, 2020	BUY	$7.81 - $18.82 $27,616 - $66,547	3,536 Added 18.25%	22,911 $314,000
Q4 2019 Feb 13, 2020	BUY	$9.73 - $19.31 $187,273 - $371,659	19,247 Added 15036.72%	19,375 $343,000
Q4 2019 Feb 12, 2020	BUY	$9.73 - $19.31 $1,245 - $2,471	128 New	128 $328,000

9.83M

30.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $92.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Capital Asset Advisory Services LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Asset Advisory Services LLC with notifications on news.